Free Trial

Carmell Q3 2023 Earnings Report

Carmell logo
$0.22 0.00 (-0.77%)
(As of 12/20/2024 05:40 PM ET)

Carmell EPS Results

Actual EPS
-$0.62
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Carmell Revenue Results

Actual Revenue
$3.73 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Carmell Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here << 

Carmell Earnings Headlines

Carmell (NASDAQ:CTCX) Shares Up 0.1% - Here's Why
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
See More Carmell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Carmell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carmell and other key companies, straight to your email.

About Carmell

Carmell (NASDAQ:CTCX) operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

View Carmell Profile

More Earnings Resources from MarketBeat

Upcoming Earnings